{"id":84489,"date":"2023-12-27T09:12:00","date_gmt":"2023-12-27T12:12:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/"},"modified":"2023-12-27T09:12:00","modified_gmt":"2023-12-27T12:12:00","slug":"consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/","title":{"rendered":"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS"},"content":{"rendered":"<p><b>PR NEWSWIRE<\/b><\/p>\n<div class=\"xn-content\">\n<p class=\"prntac\"><i>Acesso ao tratamento pode aumentar a sobrevida de pacientes no sistema p\u00fablico<\/i><\/p>\n<p><span class=\"legendSpanClass\">S\u00c3O PAULO<\/span>, <span class=\"legendSpanClass\">27 de dezembro de 2023<\/span> \/PRNewswire\/ <b>&#8212; AstraZeneca &#8211; <\/b>A CONITEC abriu a Consulta P\u00fablica n\u00ba 57 que avalia a incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o de melhora para o tratamento do c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel\u00a0no Sistema \u00danico de Sa\u00fade (SUS). Aberta at\u00e9 15 de janeiro, profissionais da sa\u00fade, pacientes, familiares e sociedade podem opinar.<\/p>\n<p>Apesar de o c\u00e2ncer de pulm\u00e3o n\u00e3o ser o tipo de tumor mais incidente, com estimativa de 32.560 novos casos por ano<sup>1<\/sup>, \u00e9 a principal causa de morte por c\u00e2ncer no Brasil e no mundo, com taxas maiores do que a soma da mortalidade dos c\u00e2nceres de pr\u00f3stata, mama e colorretal<sup>2<\/sup>. Em pacientes com CPNPC, apenas 16% dos casos s\u00e3o descobertos em est\u00e1gio inicial, com sobrevida de 5 anos de 56%<sup>3<\/sup>. J\u00e1 em est\u00e1gio III, as realidades de diagn\u00f3stico nos sistemas p\u00fablico e privado de sa\u00fade s\u00e3o discrepantes: 9,4% dos pacientes no sistema p\u00fablico descobrem a doen\u00e7a em est\u00e1gio III e 11,4%, no sistema privado<sup>4<\/sup>. Nesse est\u00e1gio, a sobrevida varia de 36% a 13% em 5 anos<sup>5<\/sup>. Ou seja, com tratamento adequado, pacientes em est\u00e1gio III poderiam ter chance de melhora. \u00a0<\/p>\n<p>Pacientes da rede privada t\u00eam m\u00e9dia de sobrevida global duas vezes maior do que os da rede p\u00fablica?. O tratamento com inten\u00e7\u00e3o curativa poderia mudar a realidade dos pacientes com CPNPC em est\u00e1gio III no SUS, com um n\u00famero significativo de pacientes vivos em 5 anos<sup>6,<\/sup><sup>7<\/sup>.<\/p>\n<p>O tratamento \u00e9 recomendado por diretrizes, como Sociedade Brasileira de Oncologia Cl\u00ednica (SBOC)<sup>8<\/sup>, National Comprehensive Cancer Network (NCCN)<sup>9<\/sup>\u00a0e European Society for Medical Oncology (ESMO)<sup>10<\/sup>. \u00a0<\/p>\n<p>Acesse <a href=\"https:\/\/www.gov.br\/participamaisbrasil\/consulta-publica-conitec-sectics-n-57-2023-opiniao-durvalumabe-para-pacientes-com-cancer-de-pulmao-de-celulas-nao-pequenas-cpcnp-estagio-iii-irressecavel-cuja-doenca-nao-progrediu-apos-terapia\" target=\"_blank\" rel=\"nofollow noopener\">aqui<\/a>.<\/p>\n<p class=\"prntac\"><b><i>BR-26803.<\/i><\/b><\/p>\n<p><sup>1<\/sup>\u00a0Instituto Nacional de C\u00e2ncer &#8211; <a href=\"https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/numeros\/estimativa\/estado-capital\/brasil\" target=\"_blank\" rel=\"nofollow noopener\">estimativa dos casos novos<\/a>. 21 set 2023.\u00a0 <br \/><sup>2<\/sup>\u00a0BRAY, F. et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality <br \/>worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, Wiley Online Library,\u00a0 <br \/>v. 68, n. 6, p. 394-424, 2018. <br \/><sup>3<\/sup>\u00a0Instituto Nacional de C\u00e2ncer &#8211; <a href=\"https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/cancer\/tipos\/pulmao\" target=\"_blank\" rel=\"nofollow noopener\">C\u00e2ncer de Pulm\u00e3o<\/a>. 21 set 2023.\u00a0 \u00a0<br \/><sup>4<\/sup>\u00a0Coelho JC et al. JCO GLOB ONCOL. 2022 Mar;8:e2100333.\u00a0 <br \/><sup>5<\/sup>\u00a0Goldstraw P, et al. J Thorac Oncol 2016;11:39-51.\u00a0 <br \/><sup>6<\/sup>\u00a0Spigel, D. et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. Presentation 8511, ASCO 2021\u00a0 <br \/><sup>7<\/sup>\u00a0Antonia Sj, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Et Al. Durvalumab After Chemoradiotherapy In Stage Iii Non-small-cell Lung Cancer. N Engl J Med. 2017;377:1919-29 <br \/><sup>8<\/sup>\u00a0SBOC. Diretrizes de tratamentos oncol\u00f3gicos &#8211; Pulm\u00e3o n\u00e3o-pequenas c\u00e9lulas: doen\u00e7a localizada e localmente avan\u00e7ada. 2021\u00a0 <br \/><sup>9<\/sup>\u00a0NCCN Version 1.2022\u00a0 <br \/><sup>10<\/sup>\u00a0Remon J, Soria JC, Peters S; ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021 Dec;32(12):1637-1642<\/p>\n<p>FONTE  AstraZeneca Brasil<\/p>\n<\/div>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n<p>A <b>OESP<\/b> n\u00e3o \u00e9(s\u00e3o) respons\u00e1vel(is) por erros, incorre\u00e7\u00f5es, atrasos ou quaisquer decis\u00f5es tomadas por seus clientes com base nos Conte\u00fados ora disponibilizados, bem como tais Conte\u00fados n\u00e3o representam a opini\u00e3o da <b>OESP<\/b> e s\u00e3o de inteira responsabilidade da <b>PR Newswire Ltda<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"PR NEWSWIRE Acesso ao tratamento pode aumentar a sobrevida de pacientes no sistema p\u00fablico S\u00c3O PAULO, 27 de dezembro de 2023 \/PRNewswire\/ &#8212; AstraZeneca &#8211; A CONITEC abriu a Consulta","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[29],"tags":[],"class_list":["post-84489","post","type-post","status-publish","format-standard","hentry","category-prnewseconomia"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS - Ag\u00eancia de Comunica\u00e7\u00e3o<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS - Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"og:description\" content=\"PR NEWSWIRE Acesso ao tratamento pode aumentar a sobrevida de pacientes no sistema p\u00fablico S\u00c3O PAULO, 27 de dezembro de 2023 \/PRNewswire\/ &#8212; AstraZeneca &#8211; A CONITEC abriu a Consulta\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Ag\u00eancia de Comunica\u00e7\u00e3o\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-27T12:12:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227\" \/>\n<meta name=\"author\" content=\"patric_oliveira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"patric_oliveira\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/\"},\"author\":{\"name\":\"patric_oliveira\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"headline\":\"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS\",\"datePublished\":\"2023-12-27T12:12:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/\"},\"wordCount\":575,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227\",\"articleSection\":[\"PR Newswire Economia\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/\",\"name\":\"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS - Ag\u00eancia de Comunica\u00e7\u00e3o\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227\",\"datePublished\":\"2023-12-27T12:12:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227\",\"contentUrl\":\"https:\\\/\\\/rt.prnewswire.com\\\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/prnewswire\\\/prnewseconomia\\\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#website\",\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\",\"name\":\"Ag\u00eancia de Comunica\u00e7\u00e3o\",\"description\":\"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/#\\\/schema\\\/person\\\/3565da46092a837cdffa42904dfc6d37\",\"name\":\"patric_oliveira\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g\",\"caption\":\"patric_oliveira\"},\"sameAs\":[\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/\"],\"url\":\"https:\\\/\\\/bluestudio.estadao.com.br\\\/agencia-de-comunicacao\\\/author\\\/patric_oliveira\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS - Ag\u00eancia de Comunica\u00e7\u00e3o","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/","og_locale":"pt_BR","og_type":"article","og_title":"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS - Ag\u00eancia de Comunica\u00e7\u00e3o","og_description":"PR NEWSWIRE Acesso ao tratamento pode aumentar a sobrevida de pacientes no sistema p\u00fablico S\u00c3O PAULO, 27 de dezembro de 2023 \/PRNewswire\/ &#8212; AstraZeneca &#8211; A CONITEC abriu a Consulta","og_url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/","og_site_name":"Ag\u00eancia de Comunica\u00e7\u00e3o","article_published_time":"2023-12-27T12:12:00+00:00","og_image":[{"url":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227","type":"","width":"","height":""}],"author":"patric_oliveira","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"patric_oliveira","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#article","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/"},"author":{"name":"patric_oliveira","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"headline":"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS","datePublished":"2023-12-27T12:12:00+00:00","mainEntityOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/"},"wordCount":575,"commentCount":0,"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#primaryimage"},"thumbnailUrl":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227","articleSection":["PR Newswire Economia"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/","name":"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS - Ag\u00eancia de Comunica\u00e7\u00e3o","isPartOf":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#primaryimage"},"image":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#primaryimage"},"thumbnailUrl":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227","datePublished":"2023-12-27T12:12:00+00:00","author":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37"},"breadcrumb":{"@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#primaryimage","url":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227","contentUrl":"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PT00844&amp;Transmission_Id=202312270700PR_NEWS_LATAM____PT00844&amp;DateId=20231227"},{"@type":"BreadcrumbList","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/prnewswire\/prnewseconomia\/consulta-publica-avalia-incorporacao-de-medicamento-com-intencao-curativa-para-cancer-de-pulmao-de-nao-pequenas-celulas-cpnpc-em-estagio-iii-irressecavel-no-sus-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"},{"@type":"ListItem","position":2,"name":"Consulta P\u00fablica avalia incorpora\u00e7\u00e3o de medicamento com inten\u00e7\u00e3o curativa para c\u00e2ncer de pulm\u00e3o de n\u00e3o pequenas c\u00e9lulas (CPNPC) em est\u00e1gio III irressec\u00e1vel no SUS"}]},{"@type":"WebSite","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#website","url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/","name":"Ag\u00eancia de Comunica\u00e7\u00e3o","description":"Conte\u00fado estrat\u00e9gico para engajar seu p\u00fablico com a expertise do Estad\u00e3o.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/#\/schema\/person\/3565da46092a837cdffa42904dfc6d37","name":"patric_oliveira","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ca7e6312c4efc0dd6566e6d38573727fdf4333d14aff8583ce79423883088a1?s=96&d=mm&r=g","caption":"patric_oliveira"},"sameAs":["https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/"],"url":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/author\/patric_oliveira\/"}]}},"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/84489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=84489"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/84489\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=84489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=84489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=84489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}